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ABSTRACT 
Background 
This review describes the safety of deferoxamine (DFO), deferiprone (DFP), deferasirox (DFX), and 
combined therapy in young patients less than 25 years of age with haemoglobinopathies. 
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Method 
Searches in electronic literature databases were performed. Studies reporting adverse events 
associated with iron chelation therapy were included. Study and reporting quality was assessed using 
AHRQ Risk of Bias Assessment Tool and McMaster Quality Assessment Scale of Harms. Prospective 
clinical studies were pooled in a random-effects meta-analysis of proportions. 
 
Results 
Safety data of 2,040 patients from 34 studies were included. 92 case reports of 246 patients were 
identified. DFX (937 patients) and DFP (667 patients) possess the largest published safety evidence. 
Fewer studies on combination regimens are available. Increased transaminases were seen in all 
regimens (3.9-31.3%) and gastrointestinal disorders with DFP and DFX (3.7-18.4% and 5.8-18.8%, 
respectively). Therapy discontinuations due to adverse events were low (0-4.1%). Reporting quality 
was selective and poor in most of the studies. 
 
Conclusion 
Iron chelation therapy is generally safe in young patients and published data corresponds to 
summary of product characteristics. Each iron chelation regimen has its specific safety risks. DFO 
seems not to be associated with serious adverse effects in recommended doses. In DFP and DFX rare, 
but serious adverse reactions can occur. Data on combined therapy is scarce, but it seems equally 
safe compared to monotherapy. 
 
KEY POINTS 
 
- Both deferiprone (DFP) and deferasirox (DFX) possess the largest published safety evidence 
in young patients. 
- However, both drugs may cause serious and severe adverse effects: agranulocytosis (DFP) 
and Fanconi syndrome (DFX). 
- Studies in children and adolescents are scarce for combined therapy, but available data 
suggests that combined regimens are equally safe to their iron chelating agents in 
monotherapy. 
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BACKGROUND 
Haemoglobin disorders such as sickle cell disease and thalassaemia account for 3.4% of all deaths in 
children under the age of 5 years (1, 2). Long-term treatment of these conditions is an emerging issue 
since more and more newborns with haemoglobinopathies survive due to the reduction of childhood 
mortality (3). 
Depending on the severity of the disease, affected patients suffer from anaemia starting in early 
childhood and commonly require regular blood transfusion therapy (4, 5). Over time chronic 
transfusion therapy leads to iron overload and, if untreated, usually results in severe organ damage.  
The overall goal of iron chelation therapy is to maintain iron levels considerably safe for the patient. 
Currently, there are three iron chelators licensed: deferoxamine (DFO), deferiprone (DFP) and 
deferasirox (DFX). Since DFO needs to be administered via parenteral routes for several hours per 
day, oral drug alternatives DFP and DFX are preferred due to better compliance. DFX is licensed in 
the EU starting from the age of 6 years and from 2 years if DFO is contraindicated or inadequate. DFP 
is indicated if DFO is contraindicated or inadequate, but available data is limited in children below the 
age of 10 years and no data is available in children under 6 years of age. Newer regimens emerged in 
the last 10 years including the combination of DFP and DFX in order to increase iron chelation 
efficacy and patient acceptance (6-8).  
Due to the early start of iron chelation therapy, a profound knowledge of efficacy and safety in young 
patients is essential. Yet only a limited amount of studies investigated the clinical properties of these 
drugs in children and young adults. In the past few years, several systematic reviews with meta-
analyses combined data of randomised controlled trials (RCT) to better evaluate the efficacy and 
safety profiles of the available iron chelating drugs (9-14). However, due to the short-term nature of 
RCTs, neglected adverse effects reporting and inability to detect rare adverse events (AE), the value 
of meta-analyses of safety data derived from RCTs is limited (15). The Cochrane Adverse Effects 
Methods Group suggests including other study types such as non-controlled clinical trials, 
observational studies and case reports in safety reviews to obtain a more real-life picture (16-18). 
To our knowledge, there are no published systematic reviews evaluating and quantifying the safety 
of iron chelating drugs strictly in the paediatric and younger adult population including studies other 
than RCTs. Therefore, we conducted this comprehensive systematic review to better describe and 
quantify the safety profiles of DFO, DFP, DFX and combination therapy in young patients less than 25 
years of age suffering from haemoglobinopathies with transfusion-dependent iron overload. 
 
METHOD 
Data sources and search strategy 
A systematic literature search was conducted in the following databases using the key elements 
‘d f  ox mi  ’, ‘d f  ip o  ’, ‘d f   si ox’   d ‘h  mo  o i op thi s’: PubMed (1948-2016 April 
13), EMBASE (1947-2016 Week 15), BIOSIS Previews/Citation Index (1969-2016 April 13), Science 
Citation Index Expanded (1970-2016 April 13), The Cochrane Library (1898-Issue 4 of 2016 April 12). 
The search was conducted in April 2016. The detailed search strategies are presented in 
Supplementary Table S1. We screened bibliographies of Micromedex DrugDex and Lexicomp 
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UpToDate drug monographs, m  uf ctu   ’s w  sit s, US Food   d D u  Admi ist  tio    d 
European Medicines Agency assessment reports, literature reviews and clinical trial registries Meta 
Register of Controlled Trials and NIH ClinicalTrials.gov. 
 
Study selection 
Only studies fulfilling the following inclusion criteria were considered: (1) population age between 0 
and 25 years, (2) diagnosis of haemoglobinopathies with transfusional iron overload, (3) reporting of 
AEs related to iron chelation therapy, and (4) providing the number of patients affected by each AE. 
The exclusion criteria were (1) publication language other than English, (2) conference abstracts or 
proceedings (except for case reports), (3) publications not reporting original data, (4) intoxication or 
accidental iron chelator overdose, (5) missing or inconclusive AE reporting, (6) patient age older than 
25 years, and (7) investigation of conditions other than haemoglobinopathies. 
A primary selection of all citations identified was performed by screening titles and abstracts. Two 
investigators independently evaluated the full texts for eligibility. Disagreements were resolved by 
consensus involving two senior investigators. 
Each study was assigned to one of the following types: RCTs, non-randomised controlled trials 
(NRCT), non-controlled clinical trials (NCT), retrospective observational studies (ROS), case-control 
studies (CC). Additionally, we identified and included eligible case reports and case series in our 
narrative review. 
 
Data collection 
Data was independently extracted by two investigators and included study centres, study design, 
interventions, study duration and follow-up, patient characteristics and reported AEs.  
 
Quality assessment 
Two investigators separately assessed the overall risk of bias (AHRQ Risk of Bias Assessment Tool 
(19)) and the AE reporting quality (McMaster Quality Assessment Scale of Harms (20)). Discrepancies 
were discussed and final assessment was assigned on agreement. If more than one publication 
reported data on one study, then each publication was assessed individually for reporting quality. 
However, the results were only considered once independent from the number of publications. 
 
Data synthesis 
Iron chelator-related AEs were assigned to system organ classes (SOC) according to the MedDRA 
classification (21). Incidences were the number of patients experiencing a drug-related AE divided by 
the number of exposed patients.  
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We quantitatively pooled the incidences in a random-effects meta-analysis of proportions for 
frequently reported AEs and AE-related permanent chelator discontinuation. Only prospective 
clinical trials were eligible for synthesis to avoid bias due to inappropriate data synthesis.  
Incidences were pooled using the ‘metaprop’ command in Stata (version 13.1, StataCorp, College 
Station, TX, USA) (22). A random effects model including Freeman-Tukey arcsine transformation of 
the incidence was used to normalise variance. For each incidence per study the 95% confidence 
interval (CI) was calculated and pooled incidence CIs were based on the exact-test statistics. 
Heterogeneity between studies and study type w s  ss ss d with Coch   ’s Q-test and percentage 
of total variation across studies due to heterogeneity was evaluated with the I2 measure (23, 24). 
Sensitivity analyses were performed to identify potential sources of heterogeneity. 
 
RESULTS 
Literature search results 
Figure 1 describes our literature search according to the PRISMA statement (25). In total, 34 studies 
comprising 2,040 young patients were included (Table 1). Reported incidences of frequently reported 
AEs are presented in Table 2. We identified 7 studies on DFO (198 patients), 13 studies on DFP (667 
patients), 15 studies on DFX (937 patients), two studies on sequential combination of DFP and DFO 
(SEQ DFP+DFO, 37 patients), one study on sequential combination of DFX and DFO (SEQ DFX+DFO, 7 
patients), 5 studies on simultaneous combination of DFP and DFO (SIM DFP+DFO, 131 patients), and 
two studies on simultaneous combination of DFP and DFX (SIM DFP+DFX, 63 patients).  
Despite several identified studies on various combination regimens using DFX and DFO (26-30), only 
one small retrospective study in 7 patients was eligible for our purposes (31). Mean investigation 
time of prospective clinical trials was 13 months (range 6-36 months). Additionally, 92 appropriate 
case studies reporting AEs in 246 patients were identified (Table 3). 
 
Meta-analysis of reported AE incidences 
We pooled the reported incidences of 27 prospective clinical trials by iron chelator regimen and AE. 
The summarised results are presented in Table 4. Supplementary Figures S1-S13 show the detailed 
forest plots of our meta-analysis. 
 
Quality assessment results 
The general risk of bias assessment revealed that there was a high risk of selection bias 
(Supplementary Table S2). Reason for that was the large amount of uncontrolled single-arm clinical 
trials without drug blinding. Performance, attrition, detection and reporting bias were generally less 
present, but in most cases publications insufficiently provided enough information to assess risk of 
bias. Naturally, randomised studies were of superior quality compared to non-randomised studies or 
observational studies. 
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The results of the McHarm assessment generally demonstrated a poor AE reporting quality 
(Supplementary Table S3). Most studies did not clearly define serious or severe adverse events. 
Furthermore, it was often not clear who and how the AEs were assessed. Most studies did not 
analyse their safety data more exhaustive, in contrast to efficacy parameters. Another problem was, 
that several studies did not clearly state whether all observed AEs were reported or only a selection. 
Positively, most clinical trials measured safety parameters in an active manner, but reporting was 
incomplete in terms of presentation of safety assessment methods and AE presentation. Many 
publications on NCTs provided more extensive AE reporting than the ones on RCTs and NRCTs. 
 
Deferoxamine (DFO) monotherapy 
Four RCTs, one NRCT and two ROS investigating the safety of DFO in 198 young patients were 
identified (32-38). Most studies administered DFO subcutaneously with doses between 40-50 mg/kg 
per day for 5-6 days per week.  
Only few AEs have been reported. Pooled incidence for reported neutropenia was 2.3% in 109 
patients. However, there was high heterogeneity since only one study found mild neutropenia in 
patients with DFO (33) whereas in two other RCTs neutropenia was not seen (32, 35). Other 
haematological AEs reported in four studies could not be established. Elevated liver enzymes were 
found with a pooled incidence of 3.9% (95%-CI 0.0-26.3). Renal, gastrointestinal, visual or ocular AEs 
have not been observed in any clinical trial. In one long-term retrospective study hearing loss was 
detected in 9 (36%) patients (38). Other identified AEs were abscess at infusion site and allergic 
reaction after infusion in one RCT (32), however, this was not reported in the other studies. 
We additionally identified 57 other publications reporting DFO-related AEs in 147 young patients. A 
summary of these findings is provided in Table 3. These case reports are generally in line with the 
information provided in the latest EU SPC (39). One notable case is the occurrence of fatal acute 
bone marrow aplasia in a 16-year-o d G   k  i   with β-TM and a high DFO dose of 80 mg/kg/day 
(40). The proposed mechanism is a direct damage of the megakaryocytes. 
 
Deferiprone (DFP) monotherapy 
We identified 4 RCTs, two NRCTs, 5 NCTs and two ROS reporting DFP-related AEs in 667 patients 
using DFP doses of 50-75 mg/kg per day (33-35, 41-52). Occurrence of mild to moderate neutropenia 
was reported in 425 patients with a pooled incidence of 7.1% (95%-CI 2.3-13.7). Agranulocytosis was 
reported in 436 patients (pooled incidence 0.002%, 95%-CI 0.0-0.7). Two observational studies 
reported neutropenia and agranulocytosis with incidences of 5.1-9.6% and 0-0.6%, respectively (49, 
51). Arthropathy was reported in 458 patients with an incidence of 10.9% (95%-CI 2.8-22.2%) with 
considerable heterogeneity. Sensitivity analysis showed that without the studies by Agarwal, 
Choudhry, and Sanjeeva the pooled incidence dropped to 2.4% (95% CI 0.6-4.8) with low 
heterogeneity. 
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Gastrointestinal symptoms including abdominal pain, nausea, vomiting and diarrhoea were other 
frequently reported in 3.7% (diarrhoea) to 18.4% (nausea) of patients. Elevated liver enzymes were 
reported by 6 clinical trials including 321 patients. We found a pooled incidence of 6.2% (95%-CI 2.1-
11.9) with moderate heterogeneity. Single cases of mild and transient serum creatinine increase, 
proteinuria, rash and thrombocytopenia were reported with pooled incidences of 0.5%, 0.6%, 2.4% 
and 4.4%, respectively. No auditory or visual toxicity has been reported. 
Additionally, we identified 16 case studies (including 27 patients) on DFP-related AEs in the literature. 
Details are summarised in Table 3. Most case studies reported occurrences of agranulocytosis or 
arthropathy. We identified two rare cases of drug-induced systemic lupus erythematosus of which 
one was fatal (53). However, the causality to DFP was discussed controversially (54, 55). Other 
identified cases are in line with the latest EU and US SPCs (56, 57). 
 
Deferasirox (DFX) monotherapy 
One RCT, one NRCT, 10 NCTs and 3 ROS were identified from the literature counting 37 patients (37, 
50, 52, 58-70). Investigated DFX doses ranged from 10 to 40 mg/kg per day. 
No cases of thrombocytopenia or agranulocytosis were found in 80 and 316 patients, respectively. 
One study identified neutropenia (pooled neutropenia incidence 0.5%, 95%-CI 0.0-4.8). Elevated liver 
enzymes were discovered in 20.0% (95%-CI 5.8-39.4) of 516 patients with considerable 
heterogeneity. Observational studies reported this AE with an incidence ranging 9.9-53.2%.  
Serum creatinine increase above the upper limit of normal (ULN) was investigated in almost all 
clinical trials (678 patients) and was seen with a pooled incidence of 2.5% (95%-CI 1.1-4.2). 
Heterogeneity was low. Proteinuria was not detected in 107 studied patients. Several gastrointestinal 
AEs have been reported with pooled incidences between 5.8% (diarrhoea) and 18.8% (vomiting). 
Cutaneous reactions, i.e. rash, were reported in 313 patients and occurred with a pooled incidence of 
3.7% (95%-CI 1.6-6.4) and low heterogeneity. Auditory or visual toxicities were not seen in these 
studies. 
We found 19 case reports and case series presenting AEs in 58 young patients with DFX therapy. The 
results are presented in Table 3. Most reports address renal adverse reactions that are commonly 
associated with DFX intake. There were no reported AEs which do not correspond to the latest EU 
SPC (71). 
 
Sequential deferiprone and deferoxamine combination (SEQ DFP+DFO) 
We identified one RCT and one NCT investigating the safety of a sequential combined regimen of 4 
days DFP plus two days DFO in 37 patients (32, 72). No haematological iron chelator-related AEs 
were found. Liver enzymes were elevated in 31.3% (95%-CI 16.4-48.2) of study participants. No renal 
AEs were identified or reported. Gastrointestinal AEs were seen in 3.3-6.7% of patients, but only 
reported in one study. Both studies investigated the occurrence of arthropathy resulting in a pooled 
incidence of 1.4% (95%-CI 0.0-10.1). Other identified AEs were dizziness and fatigue in one patient 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
with sequential combined therapy (32). We did not identify case reports of AEs related to sequential 
DFP and DFO chelation regimens. 
 
Sequential deferasirox and deferoxamine combination (SEQ DFX+DFO) 
One ROS has been identified investigating a sequential combination regimen of DFX for 4 days and 
DFO for the following three days in 7 paediatric patients. No haematological, renal or hepatic AEs 
were observed. No case reports have been identified. 
 
Simultaneous deferiprone and deferoxamine combination (SIM DFP+DFO) 
Three RCTs, one NRCT and one NCT reported safety data using a simultaneous chelation regimen of 
6-7 days DFP plus 2-6 days DFO in 131 patients. 
All studies investigated the occurrence of agranulocytosis but in only one trial this condition was seen 
in one patient (pooled incidence 0.0%, 95%-CI 0.0-1.7). Neutropenia was reported in 102 patients 
with a pooled incidence of 5.3% (95%-CI 1.3-11.1, low heterogeneity). Elevated liver enzymes were 
observed by three studies with a pooled incidence of 6.6% (95%-CI 2.0-13.3). Nausea and vomiting 
were seen in two studies with incidences of 31.6% and 35.3%, respectively. No auditory or visual AEs 
were reported. All 5 studies described arthropathy with a pooled incidence of 9.2% (95%-CI 0.6-23.7). 
Three case studies describing agranulocytosis related to simultaneous DFP and DFO combination 
were identified (Table 3). 
 
Simultaneous deferiprone and deferasirox combination (SIM DFP+DFX) 
One RCT and one NRCT investigated the safety of the combination of daily DFP and DFX in 63 young 
adults. No case of agranulocytosis was identified and pooled neutropenia incidence was 6.4% (95%-CI 
1.1-14.6). Elevated serum creatinine (>ULN) was seen in 3.7% (95%-CI 0.0-10.7) and liver enzyme 
abnormalities reported in 5.1% (95%-CI 0.5-12.7). Gastrointestinal events were only reported 
scarcely; one study reported non-occurrence of abdominal discomfort and one study reported any 
gastrointestinal event in 12.5% of patients. In 2.3% (95%-CI 0.0-8.6) of patients skin rash was 
observed. We did not identify any eligible case reports in our literature review. 
 
Discontinuation rate due to adverse events 
Discontinuation rates due to any iron chelator-related AE were reported by 25 prospective clinical 
trials and 6 observational studies. The latter reported higher rates compared to clinical trials, mostly 
likely due to the fact that they provided information of real-world iron chelator use.  
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In general, low discontinuation rates were found with pooled rates from 0.0% to 4.1%. Higher 
discontinuation rates were seen with DFP and SIM DFP+DFO, 2.4% (447 studied patients) and 4.1% 
(121 studied patients), respectively. We identified significant heterogeneity in the DFP subgroup. 
Taking the number of studied patients into account, DFX monotherapy had the lowest 
discontinuation rate of 0.2% (95%-CI 0.0-0.9) in 708 patients. 
Patients on DFP therapy most commonly discontinued therapy due to moderate-to-severe 
neutropenia, arthropathy, gastrointestinal symptoms or liver enzyme abnormalities. Rash, 
gastrointestinal symptoms or liver enzyme abnormalities led to discontinuation of DFX therapy. With 
simultaneously combined DFP and DFO, patients experiencing severe neutropenia, arthropathy and 
gastrointestinal symptoms resulted in therapy discontinuation. 
 
DISCUSSION 
Strengths and limitations 
Our systematic literature review is the first investigating all important iron chelation regimens in 
children, adolescents and young adults with haemoglobinopathies and transfusional iron overload. 
We used a structured and comprehensive methodology to identify and assess the safety information 
available in the scientific literature. We not only included RCTs in our review, but also data from 
cohort studies and case studies providing precious safety signals (73).  
However, we are aware that some data on iron chelator safety in young patients was not considered 
since we excluded studies with patients of older age or other diagnoses. Furthermore, methods for 
the meta-analysis of rare adverse events have not been fully elaborated yet and therefore the results 
need to be interpreted carefully (74). Our pooling method may not be ideal for very low incidences as 
seen with agranulocytosis. We also did not consider therapy duration and the AE incidence rate per 
person-years. Lack of observation time reporting in some studies did not allow us to calculate 
incidence rates. 
 
Adverse effects reporting quality 
RCTs are unquestionably the gold standard for investigating drug efficacy and safety, however, study 
publications are commonly focused on reporting efficacy parameters. Reports on non-randomised, 
non-controlled studies and case studies repeatedly provided more drug safety information. We can 
confirm that observation. 
In general, we noticed considerable selective reporting bias (75): most publications preferably 
reported commonly recognised AEs associated with the respective iron chelating agent. For example, 
all of our identified DFP studies reported agranulocytosis and arthropathy, and almost all of the DFX 
studies reported increased serum creatinine events, but not vice versa. Also some studies excluded 
patients with certain predispositions or history of AEs to an iron chelator (e.g. neutropenia in the 
past for DFP or renal dysfunction for DFX). Furthermore, it was not always clear whether the patients 
were naïve to iron chelation or switching from an existing regimen. Many publications reported only 
AEs exceeding a randomly defined minimum frequency (e.g. frequency at least 5%). Additionally, 
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some authors only reported specific AEs only if the investigated parameter met a certain threshold, 
e.g. liver enzymes larger than 2 times ULN, and some authors did not provide this information. 
Consequently, we observed considerable heterogeneity in our random effects meta-analysis. 
Moreover, our McHarm assessment showed that the reporting quality is generally poor and most 
publications lack clear AE definitions, assessment methods and safety reporting. 
 
General considerations 
Some AEs related to iron chelators were less specific such as liver enzyme abnormalities. These 
occurred with all regimens and iron overload itself is also a probable cause for occurrence. 
Gastrointestinal toxicity was equally seen with oral iron chelators DFP or DFX. Consequent intake 
with food and use of newer drug formulations may improve the tolerability (45, 46, 76, 77).  
 
Deferoxamine (DFO) 
We only identified five small-to-medium scale clinical trials investigating safety of DFO in young 
patients. However, many case studies in the paediatric population were published in the last 
decades. Generally, DFO seems to have a favourable safety profile without serious AEs. AE-related 
DFO therapy discontinuations were only observed in one study. Despite the one case of fatal bone 
marrow aplasia, all identified adverse reactions were consistent with the SPC. 
 
Several case studies reported systemic allergic reactions during drug administration, but mostly 
limited to high-dose regimens. These regimens seem also to be responsible for several reports on 
skeletal dysplasia and growth failure. Therefore high doses above 50 mg/kg per day should be 
avoided, especially before the age of 2-3 years (78-80). Regular ophthalmologic, otologic and 
auxologic examinations are advised in children (80). A therapeutic index (mean daily DFO dose in 
mg/kg divided by serum ferritin in ng/ml) above 0.025 seems to be associated with a high risk of 
hearing loss (81). Nevertheless, we did not observe visual or auditory toxicity in our investigated 
clinical trials. The chelation of enzyme co-factors iron, copper and zinc may be a potential mechanism 
for bone deformities and audio-visual toxicity (82, 83). There are some hints that oral 
supplementation of zinc and other minerals might improve tolerance (84).  
Another serious event associated with high doses of DFO was acute renal failure with decreased 
renal perfusion due to reduced prostaglandin synthesis or inhibition of tubular reabsorption of salts 
(85, 86). 
Some case reports identified DFO as an additional risk factor for the occurrence of Yersinia 
enterocolitica infections. Patients from Western countries seem to be affected more often (87). 
Yersinia infection is common in diseases with iron overload states and often associated with 
thalassaemia in children (88). Patients with higher iron burden and impaired immune system may be 
at greater risk as well. Experimental studies showed that DFO as a siderophore provides iron the iron-
dependent bacteria and thus potentiates its growth (89-91). Patients with fever and symptoms of 
gastroenteritis should temporarily discontinue DFO and Yersinia infection may be considered. 
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Deferiprone (DFP) 
All reported AEs were in agreement with the SPCs, expect for speculative cases of drug-induced 
systemic lupus erythematosus, cardiac failure with myocardial fibrosis and posterior subcapsular 
opacity. 
Milder neutropenia was reported in DFP-containing regimens with pooled incidences of 5.3-7.1%. 
However, this has been reported in thalassaemia generally (92), occurs also with other iron chelation 
agents (33, 62), and is also dependent on the frequency of blood count monitoring (44, 51). Due to 
the publication and reporting bias, we cannot clearly elaborate a higher risk for neutropenia with DFP 
in young patients compared to other iron chelation regimens. Mild neutropenia does not 
consequently lead to agranulocytosis and not always a permanent discontinuation necessary (43, 44, 
47). High heterogeneity found in all regimens and studies support this observation. 
Agranulocytosis was only seen in DFP-containing chelation regimens, and seems to occur more often 
in non-splenectomised patients and in the first months of treatment (33, 48, 93-95). This adverse 
reaction is probably idiosyncratic, unpredictable and not dose-dependent (80, 96, 97). Immune origin 
remains unproven and antibodies against neutrophils or myeloid precursors have not been found yet 
(96). Other potential mechanisms are maturation arrest of granulocytic lineage or decreased 
production of granulocyte colony forming units (98). Specific risk factors and pharmacogenetic 
dispositions have also not been identified yet (44, 99). Our meta-analysis shows that the incidence of 
agranulocytosis in children and adolescents may be lower than the 0.5-0.9% reported previously (94, 
95). However, due to the limitations of meta-analysis of very rare events, we need to consider a 
pooled incidence up to 0.7% (upper confidence interval). This is in agreement with previous reports 
and SPCs (56, 57, 100). Several case reports of non-fatal agranulocytosis in young patients have been 
published. From the available data we can state that dose-dependency was not obvious, most cases 
occurred between 2-15 months after initiation of treatment, and all patients recovered upon DFP 
discontinuation. 
Formerly, osteoarthropathy was a frequently observed condition in haemoglobinopathies (101). DFP 
is also commonly associated with arthropathy. The proposed mechanism is a DFP-induced shift of 
iron from tissue stores to joint fluid and subsequent formation of free radicals peroxidating synovial 
membranes by uncomplexed iron (54). Some studies observed that arthropathy is more common in 
patients with high serum ferritin and DFP doses above 100 mg/kg per day (33, 42, 54, 95), but this 
could not be confirmed by another study (43). Suspected long term effects of DFP-related 
arthropathies are bony dysplasia, deformation and impaired growth of ulnar epiphyses, metaphyses 
and physes (102). 
High heterogeneity was found in our pooled arthropathy estimate. This might be related to the 
subjective perception of arthralgia and associated symptoms, and different event assessment 
methods e.g. presence of patient questionnaires. Viprakasit et al. postulated that the quality of 
different DFP products influence the large differences in AE incidences (48). This should be further 
investigated and unfortunately most studies did not report the investigated drug brand. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Single cases of mild-to-moderate thrombocytopenia were observed in all DFP-containing regimens, 
but only one study reported a high incidence of 45.5%. Patients recovered upon temporary or 
permanent discontinuation. The impact of DFP on the platelet count needs to be further investigated 
in future studies. Currently, the data seems inconclusive due to the high heterogeneity found in our 
meta-analysis. 
Worsening of hepatic fibrosis under DFP therapy was raised by Olivieri et al. but could not be 
confirmed in later studies (93, 103-105) and was not observed in our review. Iron accumulation and 
chronic hepatitis C are currently seen as the more likely cause. 
Other identified events were neurological symptoms including cerebellar signs with dizziness, axial 
hypotonia and impaired motor coordination seen in two case reports and one clinical trial  (33, 106, 
107). 
 
Deferasirox (DFX) 
Although DFX is the latest oral iron chelator in the market, more trials including patients starting age 
2 years were found for DFX than for the other two chelators. Serious haematological AEs such as 
agranulocytosis seen in DFP have not been observed. In general, the identified AEs were in line with 
the SPC. 
Previous study showed that renal dysfunction may occur more often with DFX and also in young 
patients (108). Serum creatinine elevations were seen in approximately 2.5% of patients, but were 
also reported with DFP. Other renal abnormalities such as proteinuria were not observed. However, 
case studies reported life-threatening Fanconi syndrome (renal tubulopathy) which seems to be the 
most serious known AE to DFX. Low total iron burden might be a risk factor for its appearance (109). 
The mechanism is not yet well-understood and excessive rapid iron removal might modify renal 
haemodynamics (110, 111). Other discussed mechanisms are drug hypersensitivity reactions or direct 
toxic reaction with tubular necrosis (112, 113). Regular urinalyses and renal checks when using DFX 
are recommended to detect this condition in an early state. 
Skin rash is another DFX-associated AE we identified in 8 clinical trials, three observational studies 
and three case reports. We found an estimated incidence of 3.7% (DFX) and 2.3% (SIM DFP+DFX). 
Still, in the present studies, this rash was non-serious and reversible on DFX discontinuation. 
We also identified two case reports of serious ocular findings including decreased vision, retinopathy 
and lens opacities. Future clinical trials should assess ocular safety parameters to better understand 
this association and risk. 
 
Combined iron chelation regimens 
Previous literature suggested a shuttling hypothesis and an improved iron extraction from tissue 
when combining DFP and DFO (114, 115), and also the combination of DFX and DFO or DFX and DFP 
are anticipated to improve iron excretion (29, 116). Especially the latter regimen is particularly 
attractive because the combination of two oral iron chelating agents is expected to have an 
improved patient adherence. 
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Unfortunately, the safety evidence of any combination regimens is insufficient in young patients. 
However, taking this lack of publications and adequately sized studies into consideration, our review 
could not find a higher risk for combined regimens. Safety profiles seem to be similar to the iron 
chelating agents in monotherapy and no negative synergy has been identified. However, more 
clinical trials are necessary to support this conclusion. 
 
CONCLUSION 
Safety data from studies in young patients are generally in line with the respective SPCs. DFO in 
doses below 50 mg/kg per day seems not to be associated with serious AEs in young patients. 
However, due to its burdensome application, patients often prefer oral therapies. We were able to 
identify at least 10 clinical trials for each oral chelator reporting safety data in young patients under 
the age of 25 years. However, both DFP and DFX are associated with rare but serious AEs.  
Therapy discontinuation rates due to severe or serious AEs are generally low in all regimens. Each 
iron chelation regimen has its specific safety risks and should be considered tailoring the right 
treatment in young patients. Existing predispositions and comorbidities should be taken into account 
to avoid harmful reactions to this lifelong therapy. Combined therapy seems not to be associated 
with a higher risk for adverse reactions than monotherapy regimen, but combined regimens are 
generally less well documented. Finally, it would be desirable if publications on iron chelator studies 
report safety parameters more comprehensively in the future. 
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FIGURES & TABLES 
 
Figure 1: Literature search flow chart according to PRISMA (25) 
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Table 1: Characteristics of all identified studies 
Publication(s) Design Country Chelation regimen N Age Duration Diagnosis 
DEFEROXAMINE (DFO) 
Abdelrazik 2007 (32) RCT Egypt DFO s.c. 40 mg/kg/d (5-6 d/wk) 30 Mean±SD 14±2.4 years 12 months TM 
Aydinok 2007 (33) RCT Turkey DFO s.c. 40-50 mg/kg/d (5 d/wk) 12 Mean±SD 15.0±6.4 years (range 5-24.5) 12 months TM 
Gomber 2004 (34) RCT India DFO s.c. 40 mg/kg/d (5 d/wk) 7 Children age (age not reported) 6 months Thalassaemia 
Waheed 2014 (35) RCT Pakistan DFO s.c./i.v. 50 mg/kg/d (5 d/wk) 67 Mean±SD 6.0±6.4 years (range 4.5-16) 12 months TM 
Mashhadi 2011 (36) NRCT Iran DFO s.c. 40 mg/kg/d (5-6 d/wk) 17 Range 10-20 years (total cohort) 12 months TM 
Aydinok 2012 (37) ROS Turkey DFO s.c. 25-50 mg/kg/d (5 d/wk) 40 Median 3.1 years (range 1.3-5.9) Median 2.75 years (range 1.0-6.1) TM, SCD 
Barratt 1987 (38) ROS Australia DFO s.c. mean 57 mg/kg/d (nightly) 25 Mean 14.4 years (range 6-23) Mean 5.5 years TM 
DEFERIPRONE (DFP) 
Aydinok 2007 (33) RCT Turkey DFP oral 75 mg/kg/d (7 d/wk) 12 Mean±SD 15.9±4.2 years (range 9-23) 12 months TM 
Gomber 2004 (34) RCT India DFP oral 75 mg/kg/d (7 d/wk) 11 Children age (age not reported) 6 months Thalassaemia 
Waheed 2014 (35) RCT Pakistan DFP oral 75 mg/kg/d (7 d/wk) 67 Mean±SD 5.9±9.2 years (range 3-16) 12 months TM 
Sanjeeva 2016 (52) RCT India DFP oral 75 mg/kg/d (7 d/wk) 22 Mean±SD 7.26±2.42 years 12 months TM 
Choudhry 2004 (43) NRCT India DFP oral 50-75 mg/kg/d (7 d/wk) 51 Range 4-14 years 12 months TM 
Gomber 2016 (50) NRCT India DFP oral 75 mg/kg/d (7 d/wk) 17 Mean±SD 11.6±6.21 years (total cohort) 12 months TM 
Agarwal 1991 (41), (42) NCT India DFP oral 75-100 mg/kg/d (7 d/wk) 52 Mean±SD 13.05±2.6 years (range 7-22) Mean 14.2 months (range 3-21) TM, HbE-thal 
ElAlfy 2010 (44), (45) NCT Indonesia, Malaysia, Egypt DFP oral 50-100 mg/kg/d (7 d/wk) 100 Mean±SD 5.1±2.4 years (range 1-10) 6 months TM, HbE thal, SCD  
Makis 2013 (46) NCT Greece DFP oral 50-100 mg/kg/d (7 d/wk) 9 Mean 6.5 years (range 2-10) Mean 21.5 months (range 15-31) TM, TI, SCD 
Naithani 2005 (47) NCT India DFP oral 75 mg/kg/d (7 d/wk) 44 Mean 3.92 years (range 2.1-6.0) Median 13 months (range 1-46) TM 
Viprakasit 2013 (48) NCT Thailand DFP oral 50-100 mg/kg/d (7 d/wk) 73 Mean±SD 11.0±3.4 years (range 3.2-19) 12 months HbE thal, TM 
Borgna-Pignatti 2006 (49) ROS Italy DFP oral 75 mg/kg/d (7 d/wk) 157 Median 17.5 years (range 2.45-24.9) Median 4.3 years (range 0.02-8.9) TM 
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Belen 2016 (51) ROS Turkey DFP oral (dose not reported) 52 Range 3-18 years 12 months TM 
DEFERASIROX (DFX) 
Sanjeeva 2016 (52) RCT India DFX oral 20 mg/kg/d (7 d/wk) 19 Mean±SD 5.23±2.76 years 12 months TM 
Gomber 2016 (50) NRCT India DFX oral 30 mg/kg/d (7 d/wk) 17 Mean±SD 11.6±6.21 years (total cohort) 12 months TM 
Chandra 2011 (60) NCT India DFX oral 20-30 mg/kg/d (7 d/wk) 40 Median 13 years (range 3-18) 12 months TM 
Dhamija 2013 (61) NCT India DFX oral 20-40 mg/kg/d (7 d/wk) 50 Mean 9.62 years (range 2-18) 36 months TM 
Ejaz 2015 (68) NCT Pakistan DFX oral 20-40 mg/kg/d (7 d/wk) 100 Range 2-16 years 12 months TM 
Galanello 2006 (62) NCT Italy, France DFX oral 10-30 mg/kg/d (7 d/wk) 40 Mean±SD 10.4±4.4 years (range 2-17) 12 months TM 
Lai 2013 (63) NCT China DFX oral 10-40 mg/kg/d (7 d/wk) 117 Mean 6.8 years (range 2-19) 12 months (core study) TM 
Taher 2009 (66), (67) NCT Saudi Arabia, Syria, Oman, 
Egypt, Libanon 
DFX oral 10-30 mg/kg/d (7 d/wk) 162 Mean 9.5±3.6 years (range 2-15) 12 months (core study) TM 
Alavi 2014 (58) NCT Iran DFX oral 10-40 mg/kg/d (7 d/wk) 20 Mean±SD 8.02±0.70 years (range 2-13) 18 months TM 
Aycicek 2014 (59) NCT Turkey DFX oral 9-40 mg/kg/d (7 d/wk) 102 Mean±SD 8.8±4.3 years (range 2-17) 36 months TM 
Naderi 2014 (64) NCT Iran DFX oral 20 mg/kg/d (7 d/wk) 30 Mean±SD 4.9±3.2 years (range 2-16) 6 months TM 
Panigrahi 2012 (65) NCT India DFX oral 17.2-40 mg/kg/d (7 d/wk) 30 Median 13 years (range 2-21) 24 months TM 
Aydinok 2012 (37) ROS Turkey DFX oral 20-40 mg/kg/d (7 d/wk) 71 Median 2.6 years (range 1.2-5.9) Median 2.29 years (range 1.0-7.0) TM, SCD 
Origa 2016 (69) ROS Italy DFX oral 20-40 mg/kg/d (7 d/wk) 77 Children <18 years Median 4.1 years TM 
Tsouana 2015 (70) ROS UK DFX oral 10-40 mg/kg/d (7 d/wk) 62 Mean±SD 9.2 years (range 4.1-15.4) Mean 2.5 years SCD 
SEQUENTIAL DEFERIPRONE + DEFEROXAMINE (SEQ DFP+DFO) 
Abdelrazik 2007 (32) RCT Egypt DFP oral 75 mg/kg/d (4 d/wk) + DFO s.c./i.v. 40 mg/kg/d (2 d/wk) 30 Mean±SD 12±5.1 years 12 months TM 
Aydinok 1999 (72) NCT Turkey DFP oral 75 mg/kg/d (4 d/wk) + DFO s.c./i.v. 40-50 mg/kg/d (2 d/wk) 7 Mean±SD 9.4±3.1 years (range 6-13) 6 months TM 
SEQUENTIAL DEFERASIROX + DEFEROXAMINE (SEQ DFX+DFO) 
Jetsrisuparb 2010 (31) ROS Thailand DFX oral 20-30 mg/kg/d (4d/wk) + DFO s.c. 20-40 mg/kg/d (3 d/wk) 7 Median 12.5 years (range 8-19.9) Median 25 months (range 8-32) Thalassaemia 
SIMULTANEOUS DEFERIPRONE + DEFEROXAMINE (SIM DFP+DFO) 
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Aydinok 2007 (33) RCT Turkey DFP oral 75 mg/kg/d (7 d/wk) + DFO s.c. 40-50 mg/kg/d (2 d/wk) 12 Mean±SD 16.6±4.8 years (range 9-23) 12 months TM 
Elalfy 2015 (117) RCT Egypt, Oman DFP oral 75 mg/kg/d (7 d/wk) + DFP s.c. 40 mg/kg/d (6 d/wk) 48 Mean±SD 15.25±2.31 years (range 10-18) 12 months TM 
Gomber 2004 (34) RCT India DFP oral 75 mg/kg/d (7 d/wk) + DFO s.c. 40 mg/kg/d (2 d/wk) 10 Children age (exact age not reported) 6 months Thalassaemia 
Mashhadi 2011 (36) NRCT Iran DFP oral 70 mg/kg/d (6 d/wk) + DFO s.c. 40 mg/kg/d (2 d/wk) 19 Range 10-20 years (total cohort) 12 months TM 
Songdej 2015 (118) NCT Thailand DFP oral 50-100 mg/kg/d (7 d/wk) +DFO s.c. 35-45 mg/kg/d (2 d/wk) 42 Median 10 years (range 3-18) 36 months TM, HbE thal 
SIMULTANEOUS DEFERIPRONE + DEFERASIROX (SIM DFP+DFX) 
Elalfy 2015 (117) RCT Egypt, Oman DFP oral 75 mg/kg/d (7 d/wk) + DFX oral 30 mg/kd/d (7 d/wk) 48 Mean±SD 14.05±2.21 years (range 10-18) 12 months TM 
Gomber 2016 (50) NRCT India DFP oral 75 mg/kg/d (7 d/wk) + DFX oral 30 mg/kg/d (7 d/wk) 15 Mean±SD 11.6±6.21 years (total cohort) 12 months TM 
RCT: randomised controlled trial; NRCT: non-randomised controlled trial; NCT: non-controlled clinical trial; ROS: retrospective observational study; TM: thalassaemia major; SCD: sickle cell disease; TI: Thalassaemia intermedia; SD: standard deviation 
 
 
Table 2: Incidences of frequently reported iron chelator-related adverse events 
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  CT OBS CT OBS CT OBS CT OBS CT CT 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
Thrombocytopeniaa 0  0      0    0 0   45.5 1.4    0   0           0 0 0   0  2.4  0 
Neutropeniab 0 25  0    8.3  19.4  23.5 0 0 7 11.1 4.6 6.9 9.6 5.1  0   0   7.5 0       0 0 0 8.3 6.3   4.8 10.4 0 
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Agranulocytosisc 0 0 0 0 0   0 0 0  2 0 0 2 0 0 0 0 0.6  0  0 0   0 0       0 0 0 8.3 0 0 0 0 0 0 
HEPATOBILIARY DISORDERS 
Elevated liver enzymesd 23.3 0  0  5  0  4.5   0 3.9 12   16.4  1.3  0 15 4.9 15 16 69 12.5 53   16.7 9.9 23.4 53.2 26.7 57.1 0 0 6.3   11.9 8.3 0 
RENAL AND URINARY DISORDERS 
Elevated serum creatininee      2.5       0 0 2       0 10 2 10 6 3 2.5 0.9  2.5 3.3 4.2 1.3 4.8  0 0  2.1   2.4 6.3 0 
Proteinuria             0 0    2.7    0    0  0      24.7         2.4  0 
GASTROINTESTINAL DISORDERS 
Abdominal discomfort/pain 0          4.6  0 3.9 3 11.1  11  1.3 0 11.8  12.8 15 10 41  1.7   16.7   12.9 6.7       4.8  0 
Nausea  0   0   41.7   27.3   5.8   27.3 9.6 1.9  31.6   4.9 25  31 5      5.2 1.6    41.7   31.6    
Vomiting 0    0      27.3   3.9 6  27.3 9.6   31.6    20  15       5.2  3.3      31.6    
Diarrhoea 0              3 11.1  6.9       5    1.7   16.7  5.2 4.8 3.3          
Any GI toxicity      0        13.5 11 11.1 27.3 20.5              16.7 0 13 14.5  0   20.8    12.5  
OTHER 
Auditory toxicity 0 0  0   36 0  0    0    0       0   0        0  0 0    0   
Visual toxicity 0 0  0    0  0    0    0       0   0        0  0 0    0   
Arthropathy 0 0 0 0 0   0 9.1 1.5 40.9 41.2 0 38.5 4 11.1 9.1 2.7 3.8 6.4 5.3 0      0 0       3.3 0  8.3 18.8 10 21.1 0 16.7 6.7 
Rash      0     0  0     6.9   0 0   5 8  5 3.4   6.7 2.8 3.9 8.1     0    4.2 0 
Discontinuation due to 
drug-related AE 
0 0  4.5 0 0  0  1.5 13.6 7.8 0 0 3 0 0 12.3 0 29.3 0 0 0 2 0 0 0 2.5 1.7 0 0 3.3 0 20.8 4.8 0 0 0 8.3 0  10.5 7.1 0 0 
Incidence: number of patients with an AE divided by the number of investigated patients in percent; Grey box: not reported or authors did not provide sufficient information about this AE 
a Platelet count <100-150x109/L; b Absolute neutrophil count (ANC) <1.5x109/L (exception: Agarwal 1991, 1992 ANC <1.8x109/L); c ANC <0.5x109/L; d Varying definitions for elevations of transaminases alanine transaminase (ALT) and/or aspartate 
transaminase (AST); e Serum creatinine > upper limit of normal (ULN) or temporary discontinuation of iron chelator therapy 
CT: clinical trial; OBS: observational study 
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Table 3: Case studies reporting iron chelator-related adverse events in young patients with 
haemoglobinopathies 
 
Reported adverse events Comments 
Reported 
cases 
References 
DEFEROXAMINE (DFO) 
Local and systemic allergic reactions including 
urticaria, pruritus, hypotension, oedema 
Preferably in high-dose regimens above 50 mg/kg 
per day; desensitisation procedure successful 
8 (6, 119-124) 
Skeletal dysplasia, growth failure, bone lesions 
and bone abnormalities 
Associated with early DFO start before age 2-3 years 
and doses above 50 mg/kg per day; partially 
reversible on discontinuation 
54 
(78, 79, 125-
134) 
Sensorial reactions including hearing impairment, 
ototoxicity, deafness, optic neuropathy, visual 
loss 
Associated with young patient age, high doses of 50-
125 mg/kg/d and low serum ferritin; partially 
reversible on discontinuation 
46 
(81-84, 135-
144) 
Serious pulmonary syndrome including irregular 
respiratory rate, tachypnea, hypoxemia 
Associated with high doses above 100 mg/kg per day 
intravenously 
7 (145-147) 
Acute renal failure Including one fatal case 4 (85, 148, 149) 
Systemic Yersinia enterocolitica infection 
including abdominal pain, anorexia, diarrhoea, 
high fever, bacteraemia 
Including two fatal cases, DFO potential co-factor 28 (87, 150-164) 
Pelvic osteomyelitis 
Potential bacterial contamination from preparation 
and application of the drug 
1 (165) 
Acute bone marrow aplasia 
Fatal; high dose therapy with 80 mg/kg per day; 
proposed mechanism: direct damage of the 
megakaryocytes 
1 (40) 
DEFERIPRONE (DFP) 
Agranulocytosis and severe neutropenia including 
high fever, malaise, general weakness 
No fatalities; used DFP doses 40-105 mg/kg per day; 
recovery after DFP discontinuation; time to event in 
most cases between 2-15 months 
7 (96, 166-170) 
Arthropathies including severe bilateral knee 
pain, morning stiffness, joint warmth, swelling 
DFP doses 40-80 mg/kg per day; recovery after DFP 
discontinuation 
13 
(6, 54, 102, 
171) 
Gastric bleeding and melena - 1 (172) 
Drug-induced systemic lupus erythematosus (SLE) 
One fatal case reported; highly discussed with 
unconfirmed causality (54, 55) 
2 (53) 
Cardiac failure and myocardial fibrosis Speculative causality 1 (173) 
Posterior subcapsular opacity (PSC) with blurred 
vision 
Speculative causality 1 (174) 
Neurological symptoms and cerebellar signs 
including dizziness, axial hypotonia, nystagmus, 
impaired motor coordination, vision impairment 
Two cases used very high DFP doses of 230 mg/kg/d; 
one case with 100 mg/kg per day, no other cause 
evident; all resolved after DFP discontinuation 
3 (106, 107) 
DEFERASIROX (DFX) 
Renal dysfunction including nephrolithiasis, 
elevated serum creatinine levels, proteinuria and 
Fanconi syndrome 
DFX doses of 20-30 mg/kg per day; recovery after 
DFX discontinuation 
44 
(6, 109, 175-
183) 
Skin rash 
Resolved after DFX discontinuation; positive 
rechallenge in one case; desensitisation protocol 
successful 
5 (184-186) 
Gastric and duodenal ulcers including nausea, 
vomiting, haematemesis, abdominal pain 
Resolution after DFX discontinuation 1 (187, 188) 
Ocular reactions including decreased vision, 
retinopathy, lens opacities 
Retinopathy resolved after DFX discontinuation 4 (189, 190) 
Sensorineural hearing loss Recovery after DFX discontinuation 4 (191) 
SIMULTANEOUS DEFERIPRONE + DEFEROXAMINE (SIM) 
Agranulocytosis 
Some cases report resolution after G-CSF and DFP 
discontinuation 
11 (99, 192, 193) 
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Table 4: Pooled incidences of frequently reported iron chelator-related adverse events in 
prospective clinical trials 
 
 
DFO DFP DFX 
SEQ 
DFP+DFO 
SIM 
DFP+DFO 
SIM 
DFP+DFX 
 N PI N PI N PI N PI N PI N PI 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
Thrombocytopenia 37 
0.0 
(0.0-3.8) 
197 
4.4 
(0.0-23.7) 
80 
0.0 
(0.0-2.4) 
37 
0.0 
(0.0-3.8) 
52 
1.0 
(0.0-7.2) 
15a 
0.0 
(0.0-21.8) 
Neutropenia 109 
2.3 
(0.0-16.6) 
425 
7.1 
(2.3-13.7) 
214 
0.5 
(0.0-4.8) 
37 
0.0 
(0.0-3.8) 
102 
5.3 
(1.3-11.1) 
63 
6.4 
(1.1-14.6) 
Agranulocytosis 133 
0.0 
(0.0-0.7) 
436 
0.002 
(0.0-0.7) 
316 
0.0 
(0.0-0.4) 
37 
0.0 
(0.0-3.8) 
131 
0.0 
(0.0-1.7) 
63 
0.0 
(0.0-2.5) 
HEPATOBILIARY DISORDERS 
Increased liver 
enzymes 
109 
3.9 
(0.0-26.3) 
321 
6.2 
(2.1-11.9) 
516 
20.0 
(5.8-39.4) 
37 
31.3 
(16.4-48.2) 
102 
6.6 
(2.0-13.3) 
63 
5.1 
(0.5-12.7) 
RENAL AND URINARY DISORDERS 
Elevated serum 
creatinine 
- NR 169 
0.5 
(0.0-2.8) 
678 
2.5 
(1.1-4.2) 
7a 
0.0 
(0.0-41.0) 
90 
2.2 
(0.0-6.8) 
63 
3.7 
(0.0-10.7) 
Proteinuria - NR 142 
0.6 
(0.0-3.3) 
107 
0.0 
(0.0-1.7) 
- NR 42a 
3.4 
(0.1-12.6) 
15a 
0.0 
(0.0-21.8) 
GASTROINTESTINAL DISORDERS 
Abdominal pain/ 
discomfort 
30a 
0.0 
(0.0-11.6) 
273 
4.2 
(1.3-8.0) 
475 
11.7 
(3.3-23.6) 
30a 
6.7 
(0.8-22.1) 
42a 
4.8 
(0.6-16.2) 
15a 
0.0 
(0.0-21.8) 
Nausea 29 
0.0 
(0.0-6.5) 
203 
18.4 
(7.7-31.9) 
301 
17.1 
(5.5-32.8) 
- NR 31 
35.3 
(18.8-53.6) 
- NR 
Vomiting 47 
0.0 
(0.0-3.9) 
291 
12.2 
(4.7-22.2) 
159 
18.8 
(11.2-27.6) 
30a 
3.3 
(0.1-17.2) 
19a 
31.6 
(12.6-56.6) 
- NR 
Diarrhoea 30a 
0.0 
(0.0-11.6) 
182 
3.7 
(0.7-8.2) 
187 
5.8 
(0.2-16.3) 
30a 
3.3 
(0.1-17.2) 
- NR - NR 
OTHER 
Arthropathy 133 
0.0 
(0.0-0.7) 
458 
10.9 
(2.8-22.2) 
193 
0.0 
(0.0-1.5) 
37 
1.4 
(0.0-10.1) 
131 
9.2 
(0.6-23.7) 
63 
13.7 
(5.8-23.8) 
Rash - NR 112 
2.4 
(0.0-8.4) 
313 
3.7 
(1.6-6.4) 
- NR 48a 
0.0 
(0.0-7.4) 
63 
2.3 
(0.0-8.6) 
Discontinuation 
(drug-related AE) 
126 
1.1 
(0.0-4.7) 
447 
2.4 
(0.2-5.9) 
727 
0.1 
(0.0-0.8) 
37 
0.0 
(0.0-3.8) 
121 
4.1 
(0.0-13.1) 
63 
0.0 
(0.0-2.5) 
N: number of studied patients; PI: pooled incidence in percent with 95% confidence interval; NR: not investigated and/or 
reported in any study publication; a only one study reported this AE; if incidence is <0.001% only one decimal place is 
expressed (0.0%) 
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